Rinvoq is not recommended for certain individuals, primarily those who are breastfeeding and specific groups of children and adolescents with atopic dermatitis.
Key Considerations for Rinvoq Use
Understanding who should not take Rinvoq is crucial for patient safety. Based on available information, particular groups are advised to avoid this medication.
Individuals Who Should Not Take Rinvoq
- Breastfeeding Individuals
- Reason: It is currently unknown whether Rinvoq passes into breast milk. Due to this uncertainty and potential risks to the infant, individuals who are breastfeeding should not take Rinvoq.
- Children and Adolescents with Atopic Dermatitis (Specific Criteria)
- Age and Weight Restrictions: Rinvoq is not recommended for:
- Children under 12 years of age.
- Adolescents weighing less than 40 kg (approximately 88 pounds).
- Condition Specificity: This recommendation applies specifically to patients being treated for atopic dermatitis.
- Reason: The safety and effectiveness of Rinvoq have not been adequately studied in these specific pediatric and adolescent populations, leading to the recommendation against its use in these groups.
- Age and Weight Restrictions: Rinvoq is not recommended for:
Summary Table: Who Cannot Take Rinvoq?
| Group | Specific Condition / Reason for Not Taking Rinvoq |
|---|---|
| Breastfeeding Individuals | Unknown if the medicine passes into breast milk, potential infant risk. |
| Children Under 12 Years (for Atopic Dermatitis) | Not studied in this patient group. |
| Adolescents Weighing Less Than 40 kg (for Atopic Dermatitis) | Not studied in this patient group. |
